ImageneBio (NASDAQ:IMA) Earns Sell (E-) Rating from Analysts at Weiss Ratings

Weiss Ratings assumed coverage on shares of ImageneBio (NASDAQ:IMA) in a research report sent to investors on Wednesday morning,Weiss Ratings reports. The firm issued a sell (e-) rating on the stock.

IMA has been the topic of several other reports. Wedbush lowered their price target on ImageneBio from $25.00 to $23.00 and set a “neutral” rating on the stock in a research report on Friday, July 25th. Zacks Research downgraded ImageneBio from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 29th. Finally, Wall Street Zen raised ImageneBio to a “hold” rating in a research report on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, ImageneBio presently has an average rating of “Moderate Buy” and an average target price of $33.67.

ImageneBio Trading Up 8.3%

Shares of NASDAQ:IMA opened at $8.00 on Wednesday. ImageneBio has a 1 year low of $7.24 and a 1 year high of $23.28. The business has a fifty day simple moving average of $9.65 and a 200 day simple moving average of $13.20. The firm has a market cap of $32.08 million, a price-to-earnings ratio of -1.04 and a beta of 0.41.

ImageneBio (NASDAQ:IMA) last posted its earnings results on Thursday, July 24th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.08. On average, sell-side analysts forecast that ImageneBio will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMA. Goldman Sachs Group Inc. raised its position in ImageneBio by 62.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock worth $98,000 after purchasing an additional 29,369 shares during the last quarter. XTX Topco Ltd raised its position in shares of ImageneBio by 350.6% during the 1st quarter. XTX Topco Ltd now owns 56,452 shares of the company’s stock valued at $72,000 after acquiring an additional 43,924 shares during the last quarter. BML Capital Management LLC raised its position in shares of ImageneBio by 3.5% during the 1st quarter. BML Capital Management LLC now owns 3,710,803 shares of the company’s stock valued at $4,750,000 after acquiring an additional 124,937 shares during the last quarter. Finally, Aldebaran Capital LLC bought a new stake in shares of ImageneBio during the 1st quarter valued at $317,000. Institutional investors own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.